髓系动态 | 百尺竿头更进一步,中国儿童AML患者的治疗进展 髓系动态栏目专注于汇总髓系血液疾病最新进展,包括骨髓增生异常综合征(MDS)、急性髓系白血病(AML)、慢性髓系白血病(CML)、真性红细胞增多症(PV)、原发性骨髓纤维化(pMF)、肥大细胞增...
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351, 657–667 (2004). CAS PubMed Google Scholar Kinstrie, R. et al. Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia. Blood Adv. 1, 160–169 (2016...
DLI 最初被证明对接受去除 T 细胞移植的慢性粒细胞白血病(CML)患者有效,但随后应用于其他血液恶性肿瘤也获得不同程度的成功。在AML中,一项回顾性研究纳入 399 例HCT后首次血液学复发患者,显示DLI 治疗的 2 年OS为 21%,而未DLI的为 9%;DLI 组的多因素分析显示...
Characterization of Leukemia-Associated Antigens in Acute and Chronic Myeloid Leukemias (AML/CML)In solid tumors, immunogenic antigenshave been defined by the method of serological screening of expression libraries (SEREX). Several evidences imply T cell answers to antigens also in acute and chronic...
这段话的主角是大名鼎鼎的格列卫(甲磺酸伊马替尼,诺华研发),因为这类BCR-ABL1激酶抑制剂(TKI)的出现,慢性髓系白血病(Chronic myeloid leukemia,CML)基本从预后很差的恶性肿瘤转变为慢性疾病。 但是,包括套细胞淋巴瘤(MCL)在内的白血病类型,化疗±自体造血干细胞移植(ASCT方案)仍旧是基石疗法。最新研究表明,与单一R...
Acute myeloid leukemia (AML) is caused by altered maturation and differentiation of myeloid blasts, as well as transcriptional/epigenetic alterations, all leading to excessive proliferation of malignant blood cells in the bone marrow. Tumor heterogeneity
Previous studies have suggested that the efficacy of an MDM2i and BETi combination in chronic myeloid leukemia (CML) comes from dual targeting of the p53 and c-MYC pathways, by MDM2i and BETi respectively47. As a secondary consequence of BETi-mediated downregulation of c-MYC, BETi can ...
16、vs 30.2%)2年复发率:移植前MRD阴性患者显著低于阳性患者(17.6% vs 64.9%)移植前MRD水平有助于提示移植预后J Clin Oncol 2011; 29(11):1190-1197.荷兰、英国多中心协作组,94例儿童AML患者68%的患者可检出2个以上LAIP,26%的患者可检出1个LAIP,6%的患者无LAIPFCM检测LAIP在儿童AML患者中的应用Leukemia (20...
[6]. The criterion for AML diagnosis might differ depending on the driver mutation, yet in the majority, AML patients have ≥ 10% or 20%, if misdiagnosis with chronic myeloid leukemia (CML) might occur. Secondary AML accounts for up to 25% to 35% of total AML cases [19] with ...
Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study